TNGX Tango Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TNGX

Price (delayed)

$22.16

Market cap

$3.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$3.08B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 38

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million ...

Highlights
The equity has soared by 135% YoY and by 13% QoQ
Tango Therapeutics's quick ratio has soared by 67% from the previous quarter
The gross profit rose by 39% year-on-year but it has declined by 9% since the previous quarter
The revenue rose by 39% YoY but it fell by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://tangotx.com

Key stats

What are the main financial stats of TNGX

TNGX stock price

How has the Tango Therapeutics stock price performed over time
Intraday
3.21%
1 week
10.8%
1 month
-2.42%
1 year
577.68%
YTD
150.11%
QTD
5.93%

Financial performance

How have Tango Therapeutics's revenue and profit performed over time
Revenue
$56.99M
Gross profit
$56.99M
Operating income
-$117.53M
Net income
-$107.23M
Gross margin
100%
Net margin
-188.2%
The net margin has grown by 42% YoY but it has contracted by 16% from the previous quarter
The operating margin is up by 42% year-on-year but it is down by 16% since the previous quarter
The gross profit rose by 39% year-on-year but it has declined by 9% since the previous quarter
The revenue rose by 39% YoY but it fell by 9% QoQ

Price vs fundamentals

How does TNGX's price correlate with its fundamentals

Growth

What is Tango Therapeutics's growth rate over time

Valuation

What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
8.08
P/S
55.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
54.05
Tango Therapeutics's EPS has increased by 31% YoY and by 4.6% QoQ
The stock's P/B is 161% more than its 5-year quarterly average of 3.0 and 48% more than its last 4 quarters average of 5.3
The equity has soared by 135% YoY and by 13% QoQ
TNGX's price to sales (P/S) is 172% higher than its 5-year quarterly average of 19.9 and 103% higher than its last 4 quarters average of 26.6
The revenue rose by 39% YoY but it fell by 9% QoQ

Efficiency

How efficient is Tango Therapeutics business performance
Tango Therapeutics's return on sales has increased by 42% YoY but it has decreased by 16% QoQ
The ROE is up by 34% year-on-year and by 17% since the previous quarter
The ROA is up by 16% year-on-year and by 8% since the previous quarter
TNGX's ROIC is up by 8% YoY and by 3.2% from the previous quarter

Dividends

What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNGX.

Financial health

How did Tango Therapeutics financials performed over time
The current ratio has soared by 68% from the previous quarter
Tango Therapeutics's quick ratio has soared by 67% from the previous quarter
The debt is 92% less than the equity
The equity has soared by 135% YoY and by 13% QoQ
The debt to equity has dropped by 64% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.